Document is current
Any future updates will be listed below
-
Authors
Sharma, Rohit
Kulkarni, Rajan P.
Essner, Richard
Ward, Andrew
Lewis, Andrew H.
Guide, Shireen
Guenther, J. Michael
-
Funding
Funding for this research was provided by:
Castle Biosciences
- License Information
-
More Information
Article History
Received: 2 February 2026
Accepted: 29 May 2026
First Online: 23 June 2026
Declarations
:
: This study was funded by Castle Biosciences, Inc. Andrew H. Lewis is an employee and stock/options holder at Castle Biosciences, Inc. Andrew Ward and J. Michael Guenther are on the Speaker’s Bureau for Castle Biosciences. Rohit Sharma, Rajan P. Kulkarni, Richard Essner, and Shireen Guide have no conflicts to disclose.
: The central institutional review board approval was obtained from the WCG-IRB (reference number IRB00000533, approval number 20191435). This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Patients provided written informed consent before enrollment, and all patients enrolled underwent 31-GEP testing. Available approval numbers are provided in the supplemental Table S1.
